EP300 and hematopoietic and lymphoid cell neoplasm: Both CREBBP and p300 have HAT activity; hence, p300 inhibitors can induce synthetic lethality for CREBBP-deficient tumor cells by inhibiting compensatory p300 activation in lung and hematopoietic cancer cells through the regulation of MYC promoter activity (193).